← Leaderboards
Olga Zolotarskaya
Wynnvision, Llc
$1,914,911
Attributed
$2,774,979
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $786.2K · FY2018–24$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,774,979 · 2
By mechanism
R44$2,774,979 · 2
Top collaborators
- Xuejun Wen3 shared
Others in their field
Other Emerging Leaders on “Modification”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Mark Marino · Venturewell$49,647,567
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$31,778,457
Research focus
ModificationOryctolagus CuniculusInfectionLegal PatentNovel StrategiesEvaluationFightingHigh RiskInnovationIn VivoNew TechnologyEscherichia ColiBiomaterial CompatibilityAntibioticsAntimicrobialDesignFlasksHeavy MetalsDevicesElderlyEffectivenessIn VitroChargePathogen
Grant awards (5)
Toward urinary catheterization with long-term resistance to bacterial colonization$540,238
R44 · FY2024 · DK · contact PI
Toward urinary catheterization with long-term resistance to bacterial colonization$514,604
R44 · FY2023 · DK · contact PI
Antimicrobial and Biocompatible Endotracheal Tubes$786,197
R44 · FY2020 · HL · contact PI
Antimicrobial and Biocompatible Endotracheal Tubes$708,940
R44 · FY2019 · HL · contact PI
Antimicrobial and Biocompatible Endotracheal Tubes$225,000
R44 · FY2018 · HL · contact PI